Related Experiment Videos
[Toxic lung damage caused by mitomycin C]
G Lenci1, J Müller-Quernheim, J Lorenz
1Abteilung für Pneumologie, Johannes Gutenberg-Universität, Mainz.
Pneumologie (Stuttgart, Germany)
|March 1, 1994
Summary
Mitomycin C (MMC) can cause rare lung toxicity. This case report details a pulmonary reaction after MMC monotherapy, confirmed by bronchoalveolar lavage and lung biopsy.
Area of Science:
- Oncology
- Pulmonology
- Toxicology
Background:
- Mitomycin C (MMC) is an effective antineoplastic agent used in cancer treatment.
- Lung toxicity is a rare but serious side effect associated with MMC therapy.
- Pulmonary damage following MMC monotherapy is infrequently reported in medical literature.
Observation:
- This report details a specific case of a patient experiencing a pulmonary reaction after receiving MMC as a single agent.
- Diagnostic procedures included bronchoalveolar lavage (BAL) and a transbronchial lung biopsy.
- Radiological imaging, including CT scans and high-resolution CT (HR-CT), were utilized to assess the lung condition.
Findings:
- Bronchoalveolar lavage (BAL) results indicated lymphocyte alveolitis.
- The T lymphocytes in BAL showed a normal CD4/CD8 ratio.
- Histopathological examination of the lung biopsy revealed a florid alveolitis.
Implications:
- This case highlights the importance of recognizing and investigating pulmonary reactions in patients treated with Mitomycin C.
- Understanding the diagnostic findings (BAL, biopsy, imaging) can aid in early detection of MMC-induced lung injury.
- Further research into the mechanisms and management of Mitomycin C-related pulmonary toxicity is warranted.